 | ||||||||||||||||
|
Description: Copaxone This trial, headed by Dr. Paul Gordon, is the first important step in determining whether a completely new method of treatment, vaccination, can be used to reduce inflammation and improve the course of ALS. Glatiramer acetate (brand name Copaxone) has been tested and shown to be safe in other neurological illnesses and has proven efficacy in human multiple sclerosis. This is the first time that a vaccination strategy has been tested in ALS, and safety, tolerability, and effects on the immune system of Glatiramer acetate in patients with ALS will be assessed. We aim to determine whether vaccination with glatiramer stimulates the immune system and activates immunosuppressive proteins in patients with ALS, and to determine the appropriate dosage of glatiramer in ALS. We will also establish whether glatiramer is safe and well tolerated in conjunction with riluzole, the only currently FDA approved medication for ALS. Glatiramer’s effect on disease progression will also be measured. Data from this study will be used to design and implement a large multi-center trial-assessing efficacy of Glatiramer. For more information, please contact Kate Bednarz: keb2114@columbia.edu and phone number (212) 305-2027 |
|||||||||||||||
